Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Redini

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
International Journal of Oncology|December 6, 2005
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cellsYohann Wittrant, François Lamoureux, Kanji Mori, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2012
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcomaElisabeth Miot-Noirault, François Gouin, Marie-Mélanie Dauplat, et al.
Bone|June 6, 2006
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradationSteeve Kwan Tat, Marc Padrines, Sandrine Theoleyre, et al.
Plos One|March 7, 2014
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsBérengère Gobin, Gatien Moriceau, Benjamin Ory, et al.
American Journal of Cancer Research|May 7, 2016
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transferKevin Biteau, Romain Guiho, Mathias Chatelais, et al.
Cancer|July 14, 2011
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growthGatien Moriceau, Anke J Roelofs, Régis Brion, et al.
International Journal of Cancer|August 26, 2016
TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma modelsRomain Guiho, Kevin Biteau, Giulia Grisendi, et al.
The American Journal of Pathology|October 28, 2003
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisEva Grimaud, Luc Soubigou, Séverine Couillaud, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 30, 2011
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patientSéverine Battaglia, Sophie Dumoucel, Julie Chesneau, et al.
Cytotherapy|August 11, 2018
In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical modelsRomain Guiho, Kevin Biteau, Giulia Grisendi, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
International Journal of Oncology|December 6, 2005
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cellsYohann Wittrant, François Lamoureux, Kanji Mori, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2012
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcomaElisabeth Miot-Noirault, François Gouin, Marie-Mélanie Dauplat, et al.
Bone|June 6, 2006
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradationSteeve Kwan Tat, Marc Padrines, Sandrine Theoleyre, et al.
Plos One|March 7, 2014
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsBérengère Gobin, Gatien Moriceau, Benjamin Ory, et al.
American Journal of Cancer Research|May 7, 2016
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transferKevin Biteau, Romain Guiho, Mathias Chatelais, et al.
Cancer|July 14, 2011
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growthGatien Moriceau, Anke J Roelofs, Régis Brion, et al.
International Journal of Cancer|August 26, 2016
TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma modelsRomain Guiho, Kevin Biteau, Giulia Grisendi, et al.
The American Journal of Pathology|October 28, 2003
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisEva Grimaud, Luc Soubigou, Séverine Couillaud, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 30, 2011
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patientSéverine Battaglia, Sophie Dumoucel, Julie Chesneau, et al.
Cytotherapy|August 11, 2018
In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical modelsRomain Guiho, Kevin Biteau, Giulia Grisendi, et al.
Pageof 5